Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Medgyesy, Diana
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib	Recruiting	4	137	Europe, Japan, US, RoW	Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant	Novartis Pharmaceuticals, Novartis Pharma AG	Metastatic Breast Cancer	01/28	02/28
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	Approved for marketing	N/A		Europe, Canada, US, RoW	Olaratumab, LY3012207	Eli Lilly and Company	Soft Tissue Sarcoma